MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Ocugen EPS Ratio 2011-2026 | OCGN
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Ocugen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -0.4 | -0.3 | -0.31 | -1.46 | -0.23 | -0.99 | -0.97 | -2.42 | -6.85 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.23 | -6.85 | -1.55 |
Quarterly EPS Ratio Ocugen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | -0.04 | -0.05 | - | -0.06 | -0.1 | -0.08 | - | -0.1 | -0.09 | -0.09 | - | -0.05 | -0.13 | -0.04 | - | -0.07 | -0.19 | -0.07 | - | -3.55 | -0.58 | -1.27 | - | 0.36 | -0.51 | -0.52 | - | -0.23 | -0.25 | -0.27 | - | -0.7 | -0.61 | -0.6 | - | -0.61 | -0.58 | -0.6 | - | -19.4 | -19.9 | -5.9 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.36 | -19.9 | -1.78 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aptorum Group Limited
APM
|
-0.78 | $ 0.82 | 1.9 % | $ 4.47 M |  China |
 |
Aquestive Therapeutics
AQST
|
-0.51 | $ 4.18 | 2.32 % | $ 363 M |  USA |
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | USA |
 |
AgeX Therapeutics
AGE
|
-13.7 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-2.38 | - | 1.93 % | $ 17.4 M | USA |
 |
argenx SE
ARGX
|
-7.99 | $ 832.14 | -0.97 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M | China |
 |
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-8.28 | $ 232.76 | -0.95 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | USA |
 |
AlloVir
ALVR
|
-11.7 | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.34 | 0.27 % | $ 8.04 B |  Australia |
 |
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | USA |
 |
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | USA |
 |
Atea Pharmaceuticals
AVIR
|
-2 | $ 4.59 | -1.4 % | $ 387 M | USA |
 |
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-15.8 | - | -52.27 % | $ 4.45 M | USA |
 |
Axsome Therapeutics
AXSM
|
-3.68 | $ 165.2 | -2.79 % | $ 8.22 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
-2.52 | - | -11.76 % | $ 5.79 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-1.73 | - | - | $ 2.17 B | USA |
 |
BioDelivery Sciences International
BDSI
|
0.85 | - | -4.8 % | $ 255 M | USA |
 |
BioVie
BIVI
|
-12.1 | $ 1.25 | 0.1 % | $ 1.85 M | USA |
 |
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
-0.47 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
8.83 | $ 190.58 | -2.33 % | $ 27.9 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
2.25 | $ 61.56 | -1.7 % | $ 11.7 B | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-0.81 | - | -9.72 % | $ 5.89 M | USA |
 |
Baudax Bio
BXRX
|
-177 | - | 0.59 % | $ 63 K | USA |
 |
Aptose Biosciences
APTO
|
-36.4 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-1.62 | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
42.2 | $ 111.01 | 0.11 % | $ 27.2 B | Germany |
 |
Amneal Pharmaceuticals
AMRX
|
-0.38 | $ 14.68 | 0.1 % | $ 4.54 B | USA |
 |
Capricor Therapeutics
CAPR
|
-0.83 | $ 28.39 | 1.72 % | $ 760 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-0.27 | $ 0.35 | -55.89 % | $ 47.6 M | USA |